

HEPATOCELLULAR CARCINOMA -
CARCINOGENESIS UPDATED

I Yap

SINGAPORE MED J 1995; Vol 36: 597-599

Hepatocellular carcinoma (HCC) is a leading cause of death in many parts of sub-Saharan Africa and Asia⁽¹⁾. The majority (90%) of the primary liver cancers seen in Singapore is due to HCC⁽²⁾. Hepatocarcinogenesis is a multistep, multifactorial process. Both viral and chemical carcinogens are involved in the induction of HCC though the exact mechanism of hepatocarcinogenesis remains to be completely elucidated.

Chronic hepatitis B virus (HBV) infection has been documented as one of the most important risk factor for the development of HCC. The surface antigen of HBV (HBsAg) is frequently present in the blood and liver tissue in patients with HCC in countries where HBV carriers are common. Other evidences in supporting that HBV has an aetiologic role in HCC are: familial clustering of HCC, cirrhosis and HBV carriers; parallelism between the prevalence of HCC and the frequency of HBV carriers; frequent occurrence of HCC among HBV carriers in comparison with non-carriers within the same population and development of HCC in certain animal species infected by the indigenous hepatitis virus that is similar to human HBV. The presence of integrated HBV DNA and/or detectable viral antigens in most HCC⁽⁵⁻⁷⁾ and cultured cell lines derived from HCC^(8,9) provides further evidence for a close relationship between HBV and HCC. Recent studies have also shown that the persistent expression of HBxAg (hepatitis B X gene product) in the liver of chronic HBV infection may be important in the carcinogenesis of HCC^(10,11). This indicates that HBV probably has a direct oncogenic role in the pathogenesis of HCC other than through the pathway of chronic liver injury, regeneration and cirrhosis. An increased incidence of HCC in HBsAg-negative individuals with serological evidence of past HBV infection (positive anti-HBs and anti-HBc) has also been described. With the use of polymerase chain reaction, HBV has been shown to persist at low levels in a number of these subjects⁽¹²⁻¹⁴⁾.

Human HBV does not contain known oncogenes in its genome. The mechanisms by which HBV contributes to the pathogenesis of HCC remain unclear. However, the virus may act as an initiator through integration of the HBV genome in hepatocytes resulting in insertional mutagenesis^(15,16) and/or chromosomal deletions and translocation⁽¹⁷⁾. HBV may also initiate hepatocarcinogenesis after integration by expression

of HBxAg and/or preS/S products, which have been shown to trans-activate a variety of virus and host promoters⁽¹⁸⁻²⁰⁾. Both integration and/or HBV gene expression may alter the patterns of expression of oncogenes and/or tumour suppressor genes important to the development of HCC. Chronic HBV infection may also act in the promotion and/or progression stage of carcinogenesis by enhancing the growth of preneoplastic or neoplastic cells.

There are many epidemiological characteristics of HCC suggesting that other risk factors besides HBV infection are involved in the development of HCC. These are: 1) striking male to female difference in HCC incidence despite their similarity in HBV carrier prevalence⁽²¹⁾, 2) wide variation in age of onset of HCC in endemic areas even though most HBV carriers are infected perinatally or during early childhood⁽²²⁾, 3) great discrepancy in HCC incidence among Chinese migrants in Hong Kong, Taiwan, Singapore, Shanghai and USA⁽²²⁾, 4) extraordinarily high HCC mortality in the Southern provinces of China (especially GuangXi)^(23,24). These observations cannot be explained by the HBsAg prevalence alone and other independent risk factors including aflatoxin exposure, hepatitis C (HCV) infection, alcohol drinking are probably involved also in the pathogenesis of HCC⁽³⁾.

Aflatoxins (mycotoxins derived from *Aspergillus flavus*) have been well-documented to cause extensive hepatic necrosis when administered to animals in large doses or to result in HCC when dosed chronically. *Aspergillus flavus* and aflatoxin B₁ (AFB₁) were frequent contaminants of grains and legumes, particularly in Asia and sub-Saharan Africa, where climate and food storage techniques allow for higher quantities of AFB₁ in the food supply. High incidence of HCC is found to closely parallel the prevalence of AFB₁ - contaminated food products, thus supporting a strong epidemiological link between AFB₁ ingestion and HCC⁽²⁵⁻²⁸⁾. Several evidences support a close relationship between AFB₁ and HCC: (1) rats treated with AFB₁ have HCC developed in a dose-dependent fashion; (2) AFB₁ treatment of transgenic mice with integrated HBV DNA greatly enhanced the development of HCC as compared with mice not treated with AFB₁; (3) epidemiological studies from Swaziland showed regional differences in HCC incidence that correlate more closely with the dietary AFB₁ intake than with the incidence of HBV infection; (4) Recently, high aflatoxins and the presence of a uniform point mutation (G to T) of third base of codon 249 of the P53 tumour suppressor gene in HCC was found⁽²⁹⁻⁴⁰⁾. This finding is supported by *in vitro* studies indicating that the specific point mutation of P53 was preferentially targeted to form adducts with aflatoxin B₁^(31,32). However, these same regions are also noted to have high rates of hepatitis B infection. Inconsistent results are also observed in case-control studies^(3, 33-35) which may be due to difficulty in assessing the aflatoxin exposure at the population or individual levels accurately. Aflatoxin exposure may also

Department of Medicine
National University Hospital
5 Lower Kent Ridge Road
Singapore 119074

I Yap, MBBS, M Med (Int Med), FAMS
Associate Professor

Correspondence to: Dr I Yap
3, Mt Elizabeth
#15-01, Mt Elizabeth Medical Centre
Singapore 228510

interact with HBV in the hepatocarcinogenesis in areas where such exposure is common^(36,37). Among individuals who were HBsAg-negative, the relative risk of HCC in conjunction with positive urinary aflatoxin was 1.9, whereas for those who were HBsAg-positive, detection of urinary aflatoxin increased the relative risk to 60.1⁽³⁸⁾. Serum AFB₁ measurement may be insensitive in assessing AFB₁ exposure⁽³⁹⁾. Urinary aflatoxin metabolites and DNA - adducts reflect only recent dietary exposure to aflatoxin while assays for serum albumin adducts of aflatoxin can assess dietary intake of aflatoxin over a longer period of time which may show an even stronger association between aflatoxins and HCC. Aflatoxin B₁ DNA adduct in smeared tumour tissue from patient with HCC were detected at a rate of 70% in a recent Taiwanese study⁽⁴¹⁾. However, the causal role for aflatoxins in HCC remains to be clarified.

Several case reports of HCC in patients with Non A, Non B hepatitis (NANBH) have been published⁽⁴²⁻⁴⁵⁾. Since the development of a diagnostic immunoassay for the detection of specific HCV antibodies (anti-HCV), a link between chronic HCV infection and the development of HCC has been established. High prevalence of anti-HCV in HBsAg - negative patients with HCC have been reported⁽⁴⁶⁻⁵¹⁾ and mainly in areas where HBV infection is not endemic. The substantially increased incidence of HCC in Japan during recent decades, especially among males, has been attributed to an increasing frequency of chronic hepatitis C infection in this population. The interval between transfusion and diagnosis of HCC is around 30 years in a large cohort of Japanese patients⁽⁵¹⁾ and similar lag time between exposure to HCV and HCC development is also noted among haemophilic patients⁽⁵²⁾. Although there is convincing epidemiological evidence for a direct or indirect relationship between HCV and the development of HCC, their causal relationship remains to be determined.

The possible interaction between the HCV and HBV in the pathogenesis of HCC remains unclear. A synergistic effect between the viruses was described in patients in United States, Greece and Taiwan⁽⁵³⁻⁵⁵⁾ while no significant interaction between the viruses was found in Italian or French patients with HCC^(56,57). Integration of the HCV genome does not occur, and it acts indirectly through the pathway of chronic liver injury, regeneration and cirrhosis which has been considered premalignant. So far, cirrhosis has been found to coexist in almost all anti-HCV positive HCC patients in contrast to 60%-85% of HBsAg-positive HCC patients, suggesting that cirrhosis is a pre-requisite factor for HCC development in subjects with HCV infection. Thus, the pathogenesis role of HCV is probably different from that of HBV.

Although ethanol has not been implicated as a carcinogen by itself, a number of epidemiological studies suggest an indirect role of ethanol in hepatocarcinogenesis. HCC risk is significantly increased by alcohol consumption^(58, 59). It should be noted that HCC can be seen in alcoholics without cirrhosis⁽⁶⁰⁾. Thus, alcohol definitely has a role in the development of HCC, but its relative importance may be less than was once thought. The association is however not observed in case-control studies in countries where HBV infection are endemic^(31,61,62). In a rodent chemical carcinogenesis model, ethanol acts as a promoter⁽⁶³⁾ through induction of various enzymes, alternation of DNA repair and the immunosurveillance system and dietary deficiencies.

With progress in the understanding of basic molecular mechanisms of hepatocarcinogenesis, the biochemical aberrations that predispose the liver to the development of HCC will in due time be more fully understood. Recognition

of the conditions associated with HCC can lead to early diagnosis of patients at risk and prevention of this malignancy.

REFERENCES

- Parkin DM, Stjernsward J, Muir CS. Estimates of worldwide frequency of twelve major causes. Bull World Health Organ 1984; 62: 163-82.
- Lee HP, Chia KS, Shanmugaratnam K. Cancer incidence in Singapore 1983-1987. Singapore Cancer Registry Report No. 3. 1992: 15-6.
- Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw HF, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on HCC. Hepatology 1991; 13:398-406.
- Beasley RP. Hepatitis B virus as the etiologic agent in HCC: epidemiologic considerations. Hepatology 1982; 2 (Suppl): 21-6.
- Ray MB. Hepatitis B virus antigens in tissues. Baltimore: University Park Press, 1979 : 1-159.
- Brechot C, Pourcel C, Louise A, Rain B, Trollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human HCC. Nature 1980; 286: 533-5.
- Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of HBV DNA into the genome of liver cells in chronic liver disease and HCC. N Engl J Med 1981; 305: 1067-73.
- Thung SN, Gerber MA, Sarno E, Popper H. Distribution of five antigens in HCC. Lab Invest 1979; 41: 101-5.
- Alexander JJ. Human hepatoma cell lines. In: Okuda K, Ishak KG. eds. Neoplasms of the liver. New York: Springer-Verlag, 1987: 47-56.
- Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of HBV induces liver cancer in transgenic mice. Nature 1991; 35: 317-20.
- Wang W, London WT, Lega L, Feitelson MA. HBx antigen in liver from cancer patients with chronic hepatitis and cirrhosis. J Hepatol 1991; 14: 29-37.
- Liang TJ, Jeffers LJ, Reddy KR. Viral pathogenesis of HCC in the United States. Hepatology 1993; 18: 1326-33.
- Blum HE, Liang TJ, Galun E, Wands JR. Persistence of HBV-DNA after serological recovery from HBV infection. Hepatology 1991; 14: 56-62.
- Paterlini P, Gerken G, Nakajima E. PCR to detect HBV DNA and RNA sequences in primary liver cancers from patients negative for HBsAg. N Engl J Med 1990; 323: 80-5.
- Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a HCC. Nature 1988; 333: 669-72.
- Dejan A, Bougueleret L, Grzeschik KH, Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb and steroid receptor genes in a HCC. Nature 1986; 322: 70-2.
- Hino O, Shows TB, Rogler CE. HBV integration site in HCC at chromosome 17;18 translocation. Proc Natl Acad Sci USA 1986; 83: 8338-42.
- Twu JS, Schloemer RM. Transcriptional trans-activating function of HBV. Virology 1987; 61: 3448-53.
- Spandau DF, Lee CH. Transactivation of viral enhancers by the HBV X protein. Virology 1988; 62: 427-34.
- Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS/S region of integrated HBV DNA encodes a transcriptional transactivator. Nature 1990; 343: 457-61.
- Lin TM, Tsu T, Chen CJ. Mortality of hepatoma and cirrhosis of liver in Taiwan. Br J Cancer 1986; 54: 969-76.
- Yu MW, Tsai SF, Hsu KH, You SL, Lee SS, Lin TM, et al. Epidemiologic characteristics of malignant neoplasms in China II. Liver cancer. J Natl Pub Hlth Assoc (ROC) 1988; 6:125-38.
- Li J, Liu B, Li G. Atlas of cancer mortality in the People's Republic of China. Shanghai: China Map Press, 1979: 39-46.
- Beasley RP, Lin CC, Chien CS, Chen CJ, Hwang LY. Geographic distribution of HBsAg carriers in China. Hepatology 1982; 2: 553-6.

25. Van Rensberg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van Der Watt J, Vincent TJ, Purchase IF. HCC and dietary aflatoxin in Mozambique and Transkei. *Br J Cancer* 1985; 51: 713-26.
26. Peers FG, Gilman GA, Linsell CA. Dietary aflatoxins and human liver cancer: a study in Swaziland. *Int J Cancer* 1987; 39: 545-53.
27. Peers FG, Linsell CA. Dietary aflatoxins and liver cancer: a population based study in Kenya. *Br J Cancer* 1973; 27: 473-84.
28. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. HBV, aflatoxins and HCC in Southern GuangXi, China. *Cancer Res* 1989; 49: 2506-9.
29. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutation of P53 gene in HCC from South Africa. *Nature* 1991; 350: 429-31.
30. Hsu IC, Metcalf RA, Sun T, Welsh TA, Wang NJ, Harris CC. Mutational hotspot in the P53 gene in human hepatocellular carcinomas. *Nature* 1991; 350: 427-28.
31. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of P53 gene mutational hotspots in human cancers by etiologically defined carcinogens. *Cancer Res* 1991; 51: 6185-9.
32. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G → T in codon 249 of the P53 tumor suppressor gene in human hepatocytes. *Proc Natl Acad Sci USA* 1993; 90: 8086-90.
33. Bulatao-Jayme J, Almero EM, Castro MCA, Jardeleza MTR, Slamet LA. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. *Int J Epidemiol* 1982; 11: 112-9.
34. Campbell TC, Chen JS, Liu CB, Li JY, Parpia B. Non association of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Rep of China. *Cancer Res* 1990; 50: 6882-93.
35. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang W, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. *Cancer* 1988; 62: 2051-5.
36. Yeh FS, Mo CC, Yen RC. Risk factors for HCC in GuangXi, People's Rep of China. *Natl Cancer Inst Monogr* 1985; 69: 47-8.
37. Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M. Aflatoxin exposure, HBV infection and liver cancer in Swaziland. *Int J Cancer* 1987; 39: 545-53.
38. Ross RK, Yuan JM, Yu CC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of HCC. *Lancet* 1992; 339: 943-6.
39. Tan CK, Lo DST, Law NM, Ng HS, Chao TC. Blood aflatoxin levels in HCC in Singapore. *Singapore Med J* 1995; 36: 00-00.
40. Gan LJ, Skipper PL, Peng X, Groopman JD, Chen J, Wogan GN, et al. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B₁ intake and urinary excretion of aflatoxin M1. *Carcinogenesis* 1988; 9: 1323-5.
41. Chen CJ, Zang YJ, Lu SN, Santella RM. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with HCC. *Hepatology* 1992; 16: 1150-5.
42. Resnick RH, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A non-B posttransfusion hepatitis. *Dig Dis Sci* 1983; 28: 908-11.
43. Kiyosawa K, Akahane Y, Nagata A, Furuta S. HCC after non A non B post-transfusion hepatitis. *Am J Gastroenterol* 1987; 79: 777-81.
44. Gilliam JH, Geisinger KR, Richter JE. Primary hepatocellular carcinoma after chronic non-A, non-B post transfusion hepatitis. *Ann Intern Med* 1984; 1091: 794-5.
45. Cohen EB, Gang DL, Zeldis JB. Primary hepatocellular carcinoma following non specific non-B hepatitis with tumor DNA negative for HBV DNA. *Dig Dis Sci* 1987; 32: 1428-30.
46. Briuix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R, et al. Prevalence of antibodies to HCV in Spanish patients with HCC and hepatic cirrhosis. *Lancet* 1989; 2: 1004-6.
47. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to HCV in Italian patients with HCC. *Lancet* 1989; 2: 1006-8.
48. Ohkoshi S, Kojima H, Tawaraya H, Mijajima T, Kamimura T, Asakura H, et al. Prevalence of antibody NANB virus in Japanese patients with HCC. *Jpn J Cancer Res* 1990; 81: 550-3.
49. Yuki N, Hayashi N, Kasahara H, Hagiwara H, Katayama K, Fusamoto H, et al. HB markers anti-HCV in Japanese patients with HCC. *Dig Dis Sci* 1992; 31: 65-72.
50. Hasan F, Jeffers LJ, DeMedina M, Reddy KR, Parker T, Schiff ER, et al. Hepatitis C-associated HCC. *Hepatology* 1990; 12: 589-91.
51. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and HCC: analysis by detection of anti-HCV. *Hepatology* 1990; 12: 641-75.
52. Colombo M, Manuca PM, Brettler DB. HCC in haemophilia. *Am J Hematol* 1991; 37: 234-6.
53. Yu MC, Tong MJ, Coursaget P, Ross RK, Govendarajan S, Henderson BE. Prevalence of Hepatitis B and C viral markers in black and white patients with HCC in the United States. *J Natl Cancer Inst* 1990; 82: 1038-41.
54. Kaklamani E, Trichopoulos D, Tzonou A, Zavitsanos X, Koumantaki Y, Hatzakis A, et al. Hepatitis B and C viruses and their interaction in the origin of HCC. *JAMA* 1991; 265: 1974-6.
55. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chin SC, et al. The role of hepatitis B and C viruses in HCC in a hepatitis B endemic area. *Cancer* 1992; 69: 2052-4.
56. Simonetti RG, Camma C, Fiorella F, Cottone M, Rapicetta M, Marino L, et al. Hepatitis C virus infection as a risk factor of HCC in patients with cirrhosis. *Ann Intern Med* 1992; 116: 97-102.
57. Zarski JP, Lunel F, Dardelet D, Thelu MA, Baccard M, Perrin M, et al. Hepatitis C virus and HCC in France: detection of antibodies using two second generation assays. *J Hepatol* 1991; 13: 376-7.
58. Bassendine MF. Alcohol: a major risk factor for HCC? *J Hepatol* 1986; 2: 513-9.
59. International Agency for Research on Cancer. IARC nomographs on the evaluation of carcinogenic risks to humans: alcohol drinking Vol 44. Lyon, France: International Agency for Research on Cancer 1988: 207-15.
60. Lieber CS, Seitz HK, Carro AJ. Alcohol related diseases and carcinogenesis. *Cancer Res* 1979; 39: 2863-6.
61. Lam KC, Yu MC, Leung JWC, Henderson BE. HBV and cigarette smoking: risk factors for HCC in Hong Kong. *Cancer Res* 1982; 42: 5246-8.
62. Trichoploulos D, Day NE, Kaklamani E, Tzonou A, Munoz N, Zavitsanos X, et al. HBV, tobacco, smoking and ethanol consumption in the etiology of HCC. *Int J Cancer* 1987; 39: 45-9.
63. Takada A, Nei J, Takase S, Matsuda Y. Effects of ethanol on experimental hepatocarcinogenesis. *Hepatology* 1986; 6: 65-72.